Employment of liquisolid approach in the development optimization and evaluation of an oral disintegrating tablet of aripiprazole

P Sudheer

Article Details

Employment of liquisolid approach in the development optimization and evaluation of an oral disintegrating tablet of aripiprazole

Authors:

P Sudheer

Publisher:

Marmara University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

Journal of Research in Pharmacy Vol.27 Issue 2, pp.811-824

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001347842

pISSN:

2630-6344

Keywords:

Abstract:

 The major problems associated with the oral route of administration are low solubility, low permeability, and hepatic degradation of drugs, leading to low bioavailability issues. Therefore, in this study, a biopharmaceutics classification systems BCS class II drug aripiprazole was chosen to develop an oral disintegrating tablet using liquisolid technology to enhance the solubility and dissolution rate of the drug. Liquisolid compact of aripiprazole was prepared using polyethylene glycol PEG 400 as a nonvolatile solvent, microcrystalline cellulose MCC as a carrier, and Aerosil 200 as a coating material. The formulations were optimized via the 23-factorial design. The optimum formulation was further converted to oral disintegrating tablets with the help of the super disintegrant, cross povidone, and the produced tablets were evaluated. The water solubility of aripiprazole was observed to have increased from 4.5µgml to 0.13mgml in the liquisolid form and angle of repose was found to be reasonably passable. As was observed from the experimental design, the solvent, solvent: carrier, and carrier were seen to have a significant influence on the selected responses. The X-ray diffraction pattern of the optimized formula indicated a reduction in the peak number and the peak intensities compared to the pure drug. The tablets prepared of liquisolid compacts displayed good tableting properties. The disintegration time was found to be 40 seconds. The stability studies indicated no apparent changes in the properties after a storage period of 3 months. The liquisolid compacts are an inexpensive method of preparing oral disintegrating tablets of Aripiprazole with an assurance of suitable dissolution property of the drug.

 The major problems associated with the oral route of administration are low solubility, low permeability, and hepatic degradation of drugs, leading to low bioavailability issues. Therefore, in this study, a biopharmaceutics classification systems BCS class II drug aripiprazole was chosen to develop an oral disintegrating tablet using liquisolid technology to enhance the solubility and dissolution rate of the drug. Liquisolid compact of aripiprazole was prepared using polyethylene glycol PEG 400 as a nonvolatile solvent, microcrystalline cellulose MCC as a carrier, and Aerosil 200 as a coating material. The formulations were optimized via the 23-factorial design. The optimum formulation was further converted to oral disintegrating tablets with the help of the super disintegrant, cross povidone, and the produced tablets were evaluated. The water solubility of aripiprazole was observed to have increased from 4.5µgml to 0.13mgml in the liquisolid form and angle of repose was found to be reasonably passable. As was observed from the experimental design, the solvent, solvent: carrier, and carrier were seen to have a significant influence on the selected responses. The X-ray diffraction pattern of the optimized formula indicated a reduction in the peak number and the peak intensities compared to the pure drug. The tablets prepared of liquisolid compacts displayed good tableting properties. The disintegration time was found to be 40 seconds. The stability studies indicated no apparent changes in the properties after a storage period of 3 months. The liquisolid compacts are an inexpensive method of preparing oral disintegrating tablets of Aripiprazole with an assurance of suitable dissolution property of the drug.

 The major problems associated with the oral route of administration are low solubility, low permeability, and hepatic degradation of drugs, leading to low bioavailability issues. Therefore, in this study, a biopharmaceutics classification systems BCS class II drug aripiprazole was chosen to develop an oral disintegrating tablet using liquisolid technology to enhance the solubility and dissolution rate of the drug. Liquisolid compact of aripiprazole was prepared using polyethylene glycol PEG 400 as a nonvolatile solvent, microcrystalline cellulose MCC as a carrier, and Aerosil 200 as a coating material. The formulations were optimized via the 23-factorial design. The optimum formulation was further converted to oral disintegrating tablets with the help of the super disintegrant, cross povidone, and the produced tablets were evaluated. The water solubility of aripiprazole was observed to have increased from 4.5µgml to 0.13mgml in the liquisolid form and angle of repose was found to be reasonably passable. As was observed from the experimental design, the solvent, solvent: carrier, and carrier were seen to have a significant influence on the selected responses. The X-ray diffraction pattern of the optimized formula indicated a reduction in the peak number and the peak intensities compared to the pure drug. The tablets prepared of liquisolid compacts displayed good tableting properties. The disintegration time was found to be 40 seconds. The stability studies indicated no apparent changes in the properties after a storage period of 3 months. The liquisolid compacts are an inexpensive method of preparing oral disintegrating tablets of Aripiprazole with an assurance of suitable dissolution property of the drug.

 The major problems associated with the oral route of administration are low solubility, low permeability, and hepatic degradation of drugs, leading to low bioavailability issues. Therefore, in this study, a biopharmaceutics classification systems BCS class II drug aripiprazole was chosen to develop an oral disintegrating tablet using liquisolid technology to enhance the solubility and dissolution rate of the drug. Liquisolid compact of aripiprazole was prepared using polyethylene glycol PEG 400 as a nonvolatile solvent, microcrystalline cellulose MCC as a carrier, and Aerosil 200 as a coating material. The formulations were optimized via the 23-factorial design. The optimum formulation was further converted to oral disintegrating tablets with the help of the super disintegrant, cross povidone, and the produced tablets were evaluated. The water solubility of aripiprazole was observed to have increased from 4.5µgml to 0.13mgml in the liquisolid form and angle of repose was found to be reasonably passable. As was observed from the experimental design, the solvent, solvent: carrier, and carrier were seen to have a significant influence on the selected responses. The X-ray diffraction pattern of the optimized formula indicated a reduction in the peak number and the peak intensities compared to the pure drug. The tablets prepared of liquisolid compacts displayed good tableting properties. The disintegration time was found to be 40 seconds. The stability studies indicated no apparent changes in the properties after a storage period of 3 months. The liquisolid compacts are an inexpensive method of preparing oral disintegrating tablets of Aripiprazole with an assurance of suitable dissolution property of the drug.

Article Details

Employment of liquisolid approach in the development optimization and evaluation of an oral disintegrating tablet of aripiprazole

Authors: P Sudheer

Publisher: Marmara University

Main Topics: Pharmacology and Pharmaceutical Sciences (Other)

Journal: Journal of Research in Pharmacy Vol.27 Issue 2, pp.811-824

Document Type: Article

Publication Date: 6/2025

Document Language: English

Document ID (Org No.): 2001347842

pISSN: 2630-6344

Aripiprazole

liquisolid compacts

oral disintegrating tablets

solubility

bioavailability

Issues

Authors:

P Sudheer

Publisher:

Marmara University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

Journal of Research in Pharmacy Vol.27 Issue 2, pp.811-824

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001347842

pISSN:

2630-6344